Summary of Study ST000958

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000659. The data can be accessed directly via it's Project DOI: 10.21228/M8GX0J This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST000958
Study TitleThe Influence of Sugar, Artificial Sweeteners, and the Microbiome on Rodent TCA Concentrations (part I)
Study SummaryTargeted TCA concentrations of rodents treated with diets rich in commonly used artifically sweeteners will be assessed in this study. We hypothesized that a specific subset of plasma metabolites are generated as a result from a diet rich in commonly used artificial sweeteners and their subsequent processing by the gut microbiome, which could ultimately lead to impaired glycemic control and negative physiological health outcomes. To test this hypothesis we administered normal, high glucose, fructose, aspartame, and acesulfame potassium diets to rats for 3 weeks, followed by a plasma collection through cardiac puncture and metabolic analysis. We also treated the gut microbiota with in rats with the same diets plus bacitracin/streptomycin to observe how alterations of the microbiome influence the plasma metabolic profile in these animals. The resulting data will give us insights into the influence of high sugar and artificial sweetener diets on homeostatic metabolic processes and dive into the symbiotic relationship of the gut microbiome with this process.
Institute
Mayo Clinic
Last NameHoffmann
First NameBrian
Address8701 Watertown Plank Road Milwaukee, WI 53226
Emailbhoffmann@mcw.edu
Phone414-955-8671
Submit Date2018-04-14
Analysis Type DetailGC-MS
Release Date2020-04-15
Release Version1
Brian Hoffmann Brian Hoffmann
https://dx.doi.org/10.21228/M8GX0J
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000659
Project DOI:doi: 10.21228/M8GX0J
Project Title:Mayo Pilot and Feasibility: The Influence of Sugar, Artificial Sweeteners, and the Microbiome on Metabolism
Project Summary:As diabetes becomes a growing heath concern, afflicting nearly 25.8 million people in the United States and nearly 220 million people worldwide, there has been an increased awareness of environmental factors like diet that are contributing to the disease. In diabetic patients, a major causal factor contributing to progression of the disease is hyperglycemia, although the underlying mechanisms by which hyperglycemia impairs homeostatic processes are not well understood. While we know that early intensive glycemic control reduces the risk of cardiovascular complications in humans and rodent models, there is a large gap in studies of the etiology of hyperglycemia-induced alterations in the disease. To combat high sugar diets that could contribute to diabetes and subsequent hyperglycemia, non-caloric artificial sweeteners have become one of the most utilized food additives worldwide due to their consideration as a low caloric substitute. However, supporting scientific data as to the safety of these non-caloric artificial sweeteners is limited and controversial. The negative implications of consuming a high sugar diet on overall health have long been linked to diabetes, obesity, and resulting systemic health problems; however, it was not until recently that the negative impact of consuming artificial sweeteners in the place of sugar had been increasingly recognized. Recent evidence also suggests that a diet rich in artificial sweeteners can induce glucose intolerance through the alteration of the gut microbiome. We hypothesize that a specific subset of plasma metabolites are generated as a result from a diet rich in commonly used artificial sweeteners and their subsequent processing by the gut microbiome, which could ultimately lead to impaired glycemic control and negative physiological health outcomes. To test this hypothesis this study will 1) administer a diet high in glucose, fructose, and 4 common artificial sweeteners separately to rats followed by a plasma metabolic analysis (AIM 1) and 2) treat the gut microbiota with antibiotics in these animals to observe how alterations of the microbiome influence the plasma metabolic profile in animals receiving the altered diets (AIM 2). The resulting data will give us insights into the influence of high sugar and artificial sweetener diets on homeostatic metabolic processes and dive into the symbiotic relationship of the gut microbiome with this process. This data will provide crucial insights into the dietary use of artificial sweeteners in the replacement of sugars and how it alters metabolic pathways that could potentially lead to altered states of obesity, diabetes, and cardiovascular disease.
Institute:Mayo Clinic
Last Name:Hoffmann
First Name:Brian
Address:8701 Watertown Plank Road Milwaukee, WI 53226
Email:bhoffmann@mcw.edu
Phone:414-955-8671

Subject:

Subject ID:SU000997
Subject Type:Mammal
Subject Species:Rattus norvegicus
Taxonomy ID:10116

Factors:

Subject type: Mammal; Subject species: Rattus norvegicus (Factor headings shown in green)

mb_sample_id local_sample_id Group
SA057303Sample # 12Group 1
SA057304Sample # 38Group 1
SA057305Sample # 39Group 1
SA057306Sample # 7Group 1
SA057307Sample # 31Group 1
SA057308Sample # 6Group 1
SA057309Sample # 53Group 10
SA057310Sample # 51Group 10
SA057311Sample # 54Group 10
SA057312Sample # 50Group 10
SA057313Sample # 59Group 10
SA057314Sample # 60Group 10
SA057315Sample # 57Group 10
SA057316Sample # 20Group 2
SA057317Sample # 21Group 2
SA057318Sample # 42Group 2
SA057319Sample # 30Group 2
SA057320Sample # 10Group 2
SA057321Sample # 32Group 2
SA057322Sample # 4Group 3
SA057323Sample # 28Group 3
SA057324Sample # 19Group 3
SA057325Sample # 27Group 3
SA057326Sample # 5Group 3
SA057327Sample # 3Group 3
SA057328Sample # 47Group 4
SA057329Sample # 33Group 4
SA057330Sample # 34Group 4
SA057331Sample # 29Group 4
SA057332Sample # 14Group 4
SA057333Sample # 9Group 4
SA057334Sample # 15Group 5
SA057335Sample # 26Group 5
SA057336Sample # 43Group 5
SA057337Sample # 17Group 5
SA057338Sample # 23Group 5
SA057339Sample # 16Group 5
SA057340Sample # 2Group 6
SA057341Sample # 44Group 6
SA057342Sample # 18Group 6
SA057343Sample # 41Group 6
SA057344Sample # 25Group 6
SA057345Sample # 13Group 6
SA057346Sample # 48Group 7
SA057347Sample # 11Group 7
SA057348Sample # 35Group 7
SA057349Sample # 46Group 7
SA057350Sample # 22Group 7
SA057351Sample # 1Group 7
SA057352Sample # 8Group 8
SA057353Sample # 45Group 8
SA057354Sample # 36Group 8
SA057355Sample # 24Group 8
SA057356Sample # 37Group 8
SA057357Sample # 40Group 8
SA057358Sample # 49Group 9
SA057359Sample # 55Group 9
SA057360Sample # 56Group 9
SA057361Sample # 58Group 9
SA057362Sample # 52Group 9
Showing results 1 to 60 of 60

Collection:

Collection ID:CO000991
Collection Summary:Samples were collected by cardiac puncture and plasma was collected following standard centrifugation steps. Immediately following the samples were separated into 500 uL aliquots in 600 uL tubes and frozen in liquid nitrogen.
Sample Type:Blood (plasma)

Treatment:

Treatment ID:TR001011
Treatment Summary:We administered normal, high glucose, aspartame, and acesulfame potassium diets to rats for 3 weeks, followed by a plasma collection through cardiac puncture and metabolic analysis (Group 1-4 samples). We also treated the gut microbiota with in rats with the same diets plus bacitracin/streptomycin to observe how alterations of the microbiome influence the plasma metabolic profile in these animals (Groups 5-8). The samples here contain the fructose diet group (Group 9). We also treated the gut microbiota with in rats with the same diets plus bacitracin/streptomycin to observe how alterations of the microbiome influence the plasma metabolic profile in these animals (Groups 5-8). The samples here contain the fructose diet group with antibiotic (Group 10). For the gut microbiota experiment, during the last 10 days of the diet subsets of all groups will have bacitracin and streptomycin (B/S) provided in their drinking water (0.5g/250 mL). The resulting data will give us insights into the influence of high sugar and artificial sweetener diets on homeostatic metabolic processes and dive into the symbiotic relationship of the gut microbiome with this process. Group1 = normal diet Group2 = high glucose diet Group3 = aspartame diet Group4 = acesulfame potassium diet Group5 = rat gut microbiota normal diet + antibotics Group6 = rat gut microbiota high glucose diet + antibotics Group7 = rat gut microbiota aspartame diet + antibotics Group8 = rat gut acesulfame potassium diet + antibotics Group9 = fructose diet Group10 = rat gut fructose diet + antibotics

Sample Preparation:

Sampleprep ID:SP001004
Sampleprep Summary:TCA Concentrations

Combined analysis:

Analysis ID AN001572
Analysis type MS
Chromatography type GC
Chromatography system Agilent 7890B
Column Agilent HP5-MS (30m × 0.25mm, 0.25 um)
MS Type EI
MS instrument type Single quadrupole
MS instrument name Agilent 5977A
Ion Mode POSITIVE
Units uM

Chromatography:

Chromatography ID:CH001101
Instrument Name:Agilent 7890B
Column Name:Agilent HP5-MS (30m × 0.25mm, 0.25 um)
Chromatography Type:GC

MS:

MS ID:MS001450
Analysis ID:AN001572
Instrument Name:Agilent 5977A
Instrument Type:Single quadrupole
MS Type:EI
Ion Mode:POSITIVE
  logo